Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations
Open Access
- 18 February 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 9 (1), 60
- https://doi.org/10.1186/1471-2407-9-60
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descentBreast Cancer Research and Treatment, 2007
- MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signalingBreast Cancer Research and Treatment, 2006
- MDM2 Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor PrognosisJournal of Clinical Oncology, 2006
- MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent MannerCancer Research, 2006
- The Single Nucleotide Polymorphism IVS1+309 in Mouse Double Minute 2 Does Not Affect Risk of Familial Breast CancerCancer Research, 2006
- MDM2 protein expression is a negative prognostic marker in breast carcinomaLaboratory Investigation, 2005
- Mdm2 in growth signaling and cancerGrowth Factors, 2005
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.Journal of Neuro-Oncology, 2004
- Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian CancerJournal of Clinical Oncology, 1999